AMERICAN.COM

The Journal of the American Enterprise Institute

Email this article to a friend

Geoffrey Allan, CEO of biotechnology firm Insmed, discusses the benefits of generic competition for biologic drugs.

Your name (optional):

Your email address: (Required)

Send me a copy

Recipient's email address: (Required)

(separate multiple emails with commas)

Personal message (optional):

The e-mail address(es) entered on this page will only be used to send the requested article.